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Abstract
Background:  Rule violations among elite-level sports competitors and tragedies among
adolescents have largely defined the issue of non-medical anabolic-androgenic steroid (NMAAS)
use for the public and policy makers. However, the predominant and oft-ignored segment of the
NMAAS community exists in the general population that is neither participating in competitive
sports nor adolescent. A clearer profile of NMAAS users within the general population is an initial
step in developing a full understanding of NMAAS use and devising appropriate policy and
interventions. This survey sought to provide a more comprehensive profile of NMAAS users by
accessing a large sample of user respondents from around the United States.
Methods:  U.S.-based male NMAAS users (n  = 1955) were recruited from various Internet
websites dedicated to resistance training activities and use of ergogenic substances, mass emails,
and print media to participate in a 291-item web-based survey. The Internet was utilized to provide
a large and geographically diverse sample with the greatest degree of anonymity to facilitate
participation.
Results: The majority of respondents did not initiate AAS use during adolescence and their
NMAAS use was not motivated by athletics. The typical user was a Caucasian, highly-educated,
gainfully employed professional approximately 30 years of age, who was earning an above-average
income, was not active in organized sports, and whose use was motivated by increases in skeletal
muscle mass, strength, and physical attractiveness. These findings question commonly held views
of the typical NMAAS user and the associated underlying motivations.
Conclusion: The focus on "cheating" athletes and at risk youth has led to ineffective policy as it
relates to the predominant group of NMAAS users. Effective policy, prevention or intervention
should address the target population(s) and their reasons for use while utilizing their desire for
responsible use and education.
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Background
As many as 3 million Americans may have used anabolic-
androgenic steroids (AAS) for non-medical purposes [1].
However, concerns over non-medical AAS (NMAAS) use
have been motivated less by prevalence in the general
population than by NMAAS in two specific subpopula-
tions: athletes contravening the rules of elite-level sports
[2-5] and minors [6,7]. Such concerns essentially domi-
nated the media and policy debate when AAS control leg-
islation was enacted in 1990 and amended in 2004. In a
time marked by global terrorism and potential ecological
crises, the President of the United States stated during the
2004 State of the Union address to note that the "...use of
performance-enhancing drugs like steroids in baseball,
football and other sports is dangerous, and it sends the
wrong message – that there are shortcuts to accomplish-
ment, and that performance is more important than char-
acter" [8].
Detailed information on NMAAS and its motivations are
difficult to obtain due to the legal implications and the
subsequent wariness within the NMAAS subculture
[9,10]. Most prevalence estimates of use emerge from
larger surveys of drug use among high school and college
students [7,11-18] and are fielded periodically in school
settings [13,19], surveying large national samples. How-
ever, such surveys often collect only limited information
on NMAAS use, such as lifetime, past year, and past
month use with no data indicating the rate of repeated use
of AAS among adolescents. This focus on secondary and
collegiate students partly reflects concerns for the pro-
found effects of substance use during adolescence [20] as
well as concerns for recent rare and tragic teenage suicides
that were possibly associated with mismanaged cessation
of NMAAS use [21,22].
In the case of NMAAS use among elite athletes, although
highly visible and widely publicized, it is almost certain
that the attention garnered exaggerates the contribution to
overall prevalence of NMAAS use; such athletes likely
comprise only a minor percentage of the NMAAS using
population [7,23-25]. In fact, researchers claim that "The
large majority of anabolic steroid users are not elite ath-
letes" [8].
Though prevalence rates derived from surveys in educa-
tional settings or discussion of elite athlete use provide
useful information on use patterns and trends over time
in certain populations, they tell us nothing about the char-
acteristics of those who self-administer AAS for non-med-
ical purposes. In fact, despite calls for a more complete
characterization of NMAAS users more than 15 years ago
[26], questions still remain: Who among the general pop-
ulation are using AAS? Why and how do they use them?
When did they begin using them? Most of what is known
about the onset and patterns of, and motivations for,
NMAAS use has been derived from small, non-represent-
ative samples of users [27-29], or case reports [30]. Such
small selective samples from limited geographical areas
are not likely to accurately characterize the general
NMAAS-using population. Therefore, this survey sought
to provide a more complete profile of NMAAS users by
accessing a large sample of user respondents from around
the United States via various Internet websites and maga-
zines dedicated to resistance training activities and use of
ergogenic substances. It is hoped that the resulting infor-
mation on NMAAS use – who, what, why, when and how
– would increase understanding of those who self-admin-
ister NMAAS and thereby increase understanding relevant
to social policy, risk identification, prevention, and treat-
ment.
Methods
Recruitment strategy
The illicit nature of NMAAS use can hamper traditional
recruitment efforts. Users often have justifiable concerns
about confidentially when responding to questionnaires
in person or by mail. Conversely, the resources required to
personally interview a large representative sample of par-
ticipants can be prohibitive. Thus, most large scale surveys
focus solely on prevalence and most in-depth studies use
either small local samples or select groups (e.g., prisoners
or patients in treatment).
To circumvent those concerns, promote participation, and
facilitate recruitment, an Internet-based survey tool was
designed. The Internet has become the primary means of
buying and selling illicit AAS [31] and a primary source of
NMAAS information [32]. Most NMAAS users are likely to
be experienced with the Internet and its use in NMAAS-
related activity. This approach allowed for anonymity and
enhanced privacy and confidentiality, and also facilitated
access to a wide range of geographical areas. It has previ-
ously been used in NMAAS surveys [33,24,32]. Web-
based surveys provide a validated method for collecting
self-reports of substance use [34-36] and efficient access to
large representative samples of specialized groups [37].
Further, their validity has been supported by their consist-
ency with other data collection methods [38,39].
A written request for participation, including a brief expla-
nation of the purpose and scope of the survey, emphasiz-
ing participants' privacy and the researchers' objectivity
and interest in participants' "candor," "honesty" and
"truthfulness", was posted to several venues.
Recruitment methods
1) Internet posts – A URL link to the web-based survey was
posted on 12 online message boards where steroid discus-
sion is commonplace. The message boards attract a broadJournal of the International Society of Sports Nutrition 2007, 4:12 http://www.jissn.com/content/4/1/12
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range of individuals to discuss topics such as bodybuild-
ing, strength, fitness, diet, nutritional supplements,
sports, and NMAAS use. A link was also placed on an edu-
cational site [40] operated by one of the authors (R.C.)
These materials are known to have migrated (see # 4
below), from their original sites, although the full extent
of migration is unknown.
2) Mass emails – Three of the above-referenced message
boards sent an email requesting participation to all regis-
tered users.
3) Print media – A brief description of the survey, includ-
ing the URL, was printed in a popular bodybuilding mag-
azine (Muscular Development, 12/05).
4) Spontaneous network recruiting – Participants, on their
own (without solicitation), passed information about the
survey's existence to others.
The survey was fielded for four months. Only those with
Internet access who chose to participate after reading
about the study were included. No data is available to
compare participants to NMAAS users without Internet
access, those unaware of the survey, or those who chose
not to participate.
Instrumentation
Clicking the URL opened an informed consent page con-
structed in accord with the American Psychological Asso-
ciation (APA) Ethical Principles of Psychologists and
Code of Conduct [41]. Privacy and confidentiality were
insured in several ways: No identifying data were col-
lected. Internet Provider (IP) addresses were not logged,
so responses could not be linked to a specific computer.
Secure Sockets Layer (SSL) 128 bit encryption and 1024
bit exchange facilitated secure transfer of data. Data were
secured in an encrypted, password-protected hidden vault
on a dedicated computer. An Internet cookie placed on
respondents' machines allowed completion of the survey
over multiple sessions if desired and discouraged multiple
submissions. Respondents were informed about the
cookie and, upon starting and completing the survey, pro-
vided instructions deleting it. The survey blocked any
respondent who did not consent, indicated they were less
than 18 years old, did not use AAS for non-medical pur-
poses, or had previously taken the survey.
The survey included 291 items assessing various domains,
including demographic/background data, AAS use pat-
terns and purchasing behavior, positive and negative
physiological and psychological side effects, health and
mental health history, other drug use, and dietary prac-
tices. A subset of the data is presented herein to describe
the users of AAS, their motivations, history, methods and
practices of use.
Respondents rated the effectiveness while considering
side effects of a variety of AAS and other drugs on a 5-
point likert-type scale from 1 (very poor) to 5 (very good)
in response to the following statement: "After considering
side effects, please rate the following in how effective and
useful they are in helping you reach your goals". Respond-
ents who had not used an agent that was to be rated were
requested to skip that item. The effectiveness of ancillary
drugs were rated on 3-point likert-type scale (1 [not effec-
tive], 2 [moderately effective], 3 [highly effective]) or a
box indicating they had never used the agent. NMAAS use
motivations were rated on a 5-point likert-type scale from
1 (not a reason for use) to 5 (very important) in response
to the stem "How much do the following items (15) moti-
vate your use?" The survey software randomized the order
of presentation. Concerns for aversive effects upon cessa-
tion as motivation (negative reinforcement) were assessed
via endorsement of the following outcomes should access
to AAS be lost or AAS use ceased: "Nothing, this would not
be an issue for me", "Losing size/getting small", "Losing
strength", "Losing respect", "Being unattractive",
"Decreased ability to compete in sports" and "Other"
which allowed an open-ended response. Sports involve-
ment at the high school, college, amateur, Olympic and
professional levels, as well as occupation and age, were
obtained via open-ended questions. Dietary regimen
questions were rated on a 5-point likert-type scale.
Past behavior (e.g., age of onset of AAS use, high school
athletic activities) was also assessed. Although such que-
ries can be subject to hindsight bias, participants are nor-
mally able to reliably provide valid historical information
[42] and AAS users especially have "...an uncanny abil-
ity..." to recall their AAS use history from as many as 20
years earlier [10].
To enhance motivation and attention, skip logic was
employed; participants responded only to personally-rel-
evant items based on prior responses. For this reason, not
all participants answered all items and, therefore, the
number of responses varied from domain to domain. In
addition, not all participants responded to all relevant
items (such sporadic missing data is not uncommon in
large surveys; [43]). Hence, proportions of participants
responding to items of interest are reported. The survey
took 30–45 minutes to complete.
Data analysis
SPSS for Windows (version 13) was used for statistical
analyses. Descriptive statistics (e.g., means, medians,
modes, ranges and standard deviations) are provided
where applicable and in certain areas, descriptive compar-Journal of the International Society of Sports Nutrition 2007, 4:12 http://www.jissn.com/content/4/1/12
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isons are made with U.S. Census data. Medians were
reported rather then means when data were skewed. Scale
means, based on the 5-point likert-type format noted
above are presented in some areas. Pearson's product
movement correlations (r) evaluated relationships
between interval data.
Results
The full sample comprised 2,663 males and females from
81 countries. To control for gender and cultural differ-
ences in NMAAS use and national differences in the legal
status of AAS, this report focuses only on NMAAS use
among American males. The final analysis sample in the
current report included 1,955 American males engaged in
NMAAS use.
Who is using AAS?
Age and marital status
The average AAS user was 31.1 years of age (SD = 9.16; age
range = 18 – 76) and the median age was 29 years. An
overwhelming majority (88.5%) were Caucasian/White
(see Figure 1). About half had never been married
(51.38%), although many were currently married
(38.38%) and some were divorced (9.09%). Consistent
with the largely unwed status of the sample, most did not
have children (64.21%).
Education, employment and income
The group was well-educated; most held post-secondary
degrees (74.1%) and, compared to recent U.S. Census sta-
tistics, more had completed college and advanced degrees
and fewer had failed to graduate high school than
expected based on the general populace (see Figure 2).
Most were employed full-time (77.7%; see Figure 3) and
the overall employment rate of 98.5% was higher than for
males aged 20 years or more in the U.S. population
(72.4% as of November, 2005; [44]). The unemployment
rate for males aged 20 years and older in the U.S. in
November, 2005 was 4.3% [44], nearly three times the
1.5% unemployment rate observed among this NMAAS-
using sample. Most were employed as professionals (i.e.,
"white collar" employees; see Figure 4) with median
household income between $60,000 and $79,999 per
year, much higher than the general population
($44,684[45]; see Figure 5). Such above-average educa-
Employment Status Figure 3
Employment Status.
6.10%
1.50% 1.40%
0.10%
77.70%
7.90%
5.10%
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
Full Time
Student
PartT ime
Working Student
Unemployed
Not in LaborF o r c e / R etired/Disabled
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Level of Education Figure 2
Level of Education.
Highest Level of Education 
Obtained to Date 
AAS
Respondents *US Census 
Percent Difference 
between AAS 
Users and US 
Census
Did not graduate high school  0.9% (n=17)  16.3% -15.4%
GED 2% (n=39)  x x
High school diploma  23% (n=448)  31.1% -8.1%
Vocational school  5.1% (n=100)  3.6% 1.5%
Bachelor degree  33.2% (n=647)  15.6% 17.6%
Master degree  7.6% (n=149)  5.5% 2.1%
Professional degree (e.g., MD, 
JD) 3.7% (n=72)  1.4% 2.3%
Doctorate 1.5% (n=30)  1.0% 0.5%
*U.S. Census Bureau [http://www.census.gov/prod/2005pubs/p70-98.pdf]
**U.S. Census Bureau statistics from 2001 for American's 18 years and older; includes females 
***Several respondents are current college students which would change the number of those with a high 
    school diploma to 18.92% (n=369). 
****X= Data not available 
Race/Ethnicity Figure 1
Race/Ethnicity.
Race/Ethnicity N Percent
Caucasian/White 1727 88.5%
Hispanic/Latino 83 4.3%
Multi or Biracial 41 2.1%
Asian 26 1.3%
African-American 25 1.3%
Native American 19 1.0%
Middle Eastern 12 0.6%
Other 11 0.6%
Pacific Islander/Native Hawaiian 7 0.4%Journal of the International Society of Sports Nutrition 2007, 4:12 http://www.jissn.com/content/4/1/12
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tional and occupational functioning appear consistently
among AAS users (see also [25]).
Users' perceptions
Compared to others, respondents considered their drive
and motivation in the "average/above average to above
average" range. Most responded as setting "average/high
to high" goals and a majority (70.2%) self-identified as
"perfectionists". They tended to view "some to some/all"
of life as a competition and felt that "half to most (75%)"
of daily activities focused on goal achievement.
In sum, NMAAS use was associated with a relatively high
level of functioning. Users self-identified as being driven
and motivated, viewed life competitively, and focused on
goal achievement. It must be noted, however, that,
although Internet surveys are a validated methodology
and 70% of Americans (82% of those between the ages of
18 and 49) use the Internet [46], the possibility that the
use of an Internet survey strategy could have lead to an
over-sampling of those with higher education and socio-
economic status cannot be completely ruled out.
What agents are being used and how are they obtained?
Popularity of various AAS agents
Reports of use and effectiveness ratings while considering
side effects were obtained for 15 AAS agents. Single ester
testosterones, methandrostenolone, and nandrolone
decanoate were the most commonly used agents and sin-
gle and multi-ester testosterones and trenbolone were
Prevalence and Ratings for Various Agents Figure 6
Prevalence and Ratings for Various Agents.
Agent Prevalence Rating**
Anadrol (oxymetholone)*
37.7%
(n = 753) 3.6
Anavar (oxandrolone)*
37%
(n = 724) 3.8
Clenbuterol^
49.5%
(n = 967) 3.4
Dianabol (methandrostenolone)*
64.9%
(n = 1269) 4
Deca Durabolin (nandrolone decanoate)*
63.5%
(n = 1242) 4
Dynabolan (nandrolone undecanoate)*
19.8%
(n = 388) 3.3
Equipoise (boldenone undecanoate)*
53.9%
(n = 1053) 4
Furzabol*
12.2%
(n = 238) 2.6
Halotestin (fluoxymesterone)*
19.4%
(n = 380) 3
Human Growth Hormone`
27.9%
(n = 545) 4.1
IGF-1`
19.4%
(n = 380) 3.8
Masterone (drostanolone)*
20%
(n = 391) 3.7
Methyltestosterone*
26.1%
(n = 346) 2.7
Primobolan (methenolone)*
28.2%
(n = 551) 3.7
Insulin`
21.5%
(n = 421) 3.6
Multi Ester Testosterone*
56%
(n = 1094) 4.4
Single Ester Testosterone*
78.2%
(n = 1529) 4.7
T3/T4^
37%
(n = 722) 3.5
Trenbolone*
51.3%
(n = 1002) 4.5
Winstrol (stanozolol)*
56%
(n = 1094) 3.8
  *=AAS
  ^=thermogenic agent
  `=peptide
  ** rating scale = 1 (very poor), 2(poor), 3 (acceptable), 4 (good), 5 (very good)
Occupations Figure 4
Occupations.
Occupation N Occupation N
Athlete/Coach 8 Health Care 112
Banking/Finance/Accounting 92 IT/Computer 99
Business Owner/Self Employed 130
Law Enforcement/Fire 
Fighter/Corrections/Security/Bouncer 77
Customer Service/Service 49 Legal 20
Engineering/Architect 93 Military 30
Entertainment/Art 54 Sales/Marketing 149
Executive/Management 194 Scientist/Education 57
Fitness Industry/Personal Trainer 76 Skilled Labor/Labor 213
*Table does not include all occupations
**Respondents who listed a job and student status are not included in these figures
Annual Household Income Figure 5
Annual Household Income.
23.80%
50%
23.40%
2.80%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
0-$39,999 $40,000-$99,999 $100,000-$299,999 $300,000 Journal of the International Society of Sports Nutrition 2007, 4:12 http://www.jissn.com/content/4/1/12
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rated most effective/useful (see Figure 6. Average total AAS
dosages ranged from <200 mg (n = 59, 3.6%) to more
then 5,000 mg/week (n = 2, 0.1%) with an average of
500–1000 mg/week. The highest dosage of testosterone
used for four or more weeks had considerable variability
with an average dosage of 797.5 mg/week (sd = 540.11,
range = <200 to 10,000 mg/week). Typical weekly testo-
sterone and methandrostenolone dosages are listed in Fig-
ures 7 and 8 respectively.
NMAAS users also make use of thermogenic agents. These
agents are primarily used to reduce body fat with some
providing the additional ergogenic benefit of beta-adren-
ergic stimulation (see Figure 6). NMAAS users have also
complemented the ergogenic pharmacopeia to include
peptide hormones (e.g., human growth hormone (HGH),
insulin-like growth factor (IGF-1), insulin; see Figure 6).
Ancillary drugs are also used by NMAAS users to prevent
or treat side effects or increase the effectiveness of AAS (see
Figure 9).
Methods of obtaining AAS
Consistent with the Internet having become a major
source for obtaining AAS, half of our sample (52.7%) had
purchased AAS over the Internet. Smaller percentages
obtained AAS via local sources (16.7%), friends or train-
ing partners (15%), physician's prescription (6.6%), or
transporting them from foreign countries (5.8%). Some
participants reported using multiple methods for procure-
ment and others (0.92%, n = 18), in keeping with privacy/
confidentiality concerns, were reluctant to provide this
information.
Why are AAS being used?
Positive motivations/reasons for AAS use
The most highly-rated motivations were increased muscle
mass, increased strength and enhanced physical appear-
ance (see Figure 10). Other relevant but less highly-rated
factors included increased confidence, decreased fat,
improved mood and attraction of sexual partners. Injury
prevention, recreational weightlifting, increased endur-
ance, amateur bodybuilding, amateur/recreational sports
and power lifting were rarely endorsed motives. AAS' psy-
chotropic effects have been posited as a means whereby
AAS dependence might occur [47]; however, virtually all
users in our sample (98.8%) denied injecting AAS in order
to get "high."
Athletics as a motivator
The literature suggests that NMAAS use is rarely, in a sta-
tistical sense, motivated by sports participation. Our data
showed this as well; 85.1% and 89.2% of NMAAS users,
respectively, reported that professional bodybuilding and
professional sports did not motivate their NMAAS use,
making these the least motivating factors. Only 6.3% and
5.8% respectively indicated bodybuilding and profes-
sional sports were "very important" factors in their desire
to use AAS.
Involvement in any sport, including high school, college,
amateur, Olympic or professional sports was rare; most
were not involved in organized sport (89%) even when
non-traditional sports, such as mixed martial arts, and rec-
reational activities, such as amateur baseball, were
included (see Figure 11). At the most common level of
organized sports, high school athletics, 81.8% of current
users had not participated in high school sport [s]. A
minority (4.1%) had played a high school sport and used
AAS prior to age 18, although data on the concurrence of
these behaviors was not available. Although, as with ath-
letics, bodybuilding is often seen as a major motivation
for NMAAS, 84.34% had never competed in any body-
building contest, while 15.54% competed as amateurs
and only 0.10% had competed professionally in body-
building.
Typical Daily Methandrostenolone Dosage Figure 8
Typical Daily Methandrostenolone Dosage.
Methandrostenolone
11.50%
0.50%
17.60%
46.50%
20.70%
1.60%
1.40%
0.20%
0.00% 10.00% 20.00% 30.00% 40.00% 50.00%
Wouldn't use
<5 mg/day
5-20 mg/day
25-40 mg/day
45-60 mg/day
65-80 mg/day
85-100 mg/day
105+ mg/day
Typical Weekly Testosterone Dosage Figure 7
Typical Weekly Testosterone Dosage.
Testosterone
3.60%
2.40%
52%
31.80%
1.10%
1.10%
8.10%
0% 10% 20% 30% 40% 50% 60%
Never used testosterone
<200 mg/week
200-599 mg/week
600-999 mg/week
1,000-1,399 mg/week
1,400-1,799 mg/week
1,800+ mg/weekJournal of the International Society of Sports Nutrition 2007, 4:12 http://www.jissn.com/content/4/1/12
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Negative reinforcement/reasons to continue NMAAS
Complementary to the positive reinforcement motiva-
tions endorsed, when asked about aversive factors moti-
vating continued use (i.e., concerns over cessation), loss
of muscle mass was the most frequent concern (37%), fol-
lowed by strength loss (27.2%), decreased attractiveness
(12.4%), decreased physical ability (7.2%) and loss of
respect (6%). Notably, 30.6% considered the possible loss
of access to AAS a non-issue.
Effects of age and life stage on motivation for NMAAS
Increasing age within the sample was associated with
decreases in several motivations for NMAAS; professional
bodybuilding [r(1707) = -.126; p = .001], attracting sexual
partners [r(1754) = -.105; p = .001], increasing muscle
mass [r(1801) = -.103; p  = .001], professional sports
[r(1712) = -.097; p = .001], preventing injury [r(1738) = -
.094; p = .001], recreational weightlifting [r(1703)= -.090;
p = .001], amateur/recreational sports [r(1714) = -.088; p
= .001], increasing strength [r(1708) = -.078; p = .001],
and increasing confidence [r(1758) = -.061; p  = .010].
Conversely, older AAS users were more motivated by
decreasing fat [r(1771) = .124, p = .001]. Most of these
changes, such as age-related decreases in a desire for
increased muscle, strength, and sexual attraction and
increased interest in fat reduction appear to reflect
expected shifts in focus based on development. Improving
mood, appearance, endurance, power lifting and amateur
bodybuilding were not correlated with age.
When are AAS being used?
Age of initial NMAAS and use history
Estimates for 2005 suggested that 2.6% of 12th graders
had used AAS in their lifetime, down from a high of 4.0%
Ancillary Drugs Figure 9
Ancillary Drugs.
Ancillary Drug Prevalence
Mean 
Rating Reason for Use
Accutane 7.7% (n = 151) 2.7 Prevent or treat acne
Antidepressants 9.3% (n = 182) 2.1 Mood elevation
Arimidex (anastrozole) 41.1% (n = 804) 2.6
Prevent estrogen side effects via 
halting the conversion of excess 
androgens into estrogen
Aromasin (exemestane) 8.1% (n = 160) 2.7
Prevent estrogen side effects via 
halting the conversion of excess 
androgens into estrogen
Antianxiety medications 11.2% (n = 219) 2.3 Reduce anxiety
Blood pressure medications 9.7% (n = 190) 2.4 Reduce blood pressure
Clomid (clomiphene citrate) 61.9% (n = 1210) 2.4
Estrogen antagonist used to 
prevent estrogen related side 
effects / stimulate FSH to elevate 
reduced testosterone levels 
during a cycle
Femara (letrozole) 14.4% (n = 281) 2.7
Prevent estrogen side effects via 
halting the conversion of excess 
androgens into estrogen / 
stimulate FSH to elevate reduced 
testosterone levels during a cycle
Proscar, Propecia (finasteride) 10.8% (n = 211) 2.1
Alpha reductase inhibitor which 
blocks the conversion of 
testosterone into DHT / used to 
prevent balding
Human Chorionic Gonadrotropin (HCG) 43% (n = 840) 2.6
Reverse or prevent testicular 
atrophy by acting like LH and 
stimulating Leydig cells
Nolvadex (tamoxifen citrate) 65.3% (n = 1277) 2.6
Estrogen antagonist used to 
prevent estrogen related side 
effects (e.g., gynocomastia)  / 
stimulate FSH to elevate reduced 
testosterone levels during a cycle
Sleeping medications 22.7% (n = 444) 2.6 Sleep aid
Viagra (sildenafil citrate); Cialis (tadalafil) 27.5% (n = 538) 2.6 Treatment of erectile dysfuntion
* Rating scale = 1 (not effective), 2 (moderatley effective), 3 (highly effective) or a box indicating they had
  never used the agentJournal of the International Society of Sports Nutrition 2007, 4:12 http://www.jissn.com/content/4/1/12
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in 2002 [19]. This study addresses a slightly different
question: What is the average age of initiation and the
prevalence of adolescent NMAAS use onset among adults
who are currently using AAS? That is, do most adult users
initiate NMAAS as adolescents?
The average age of NMAAS use onset was 25.81 years old
(sd = 8.26), agreeing with other reports of NMAAS use
onset in the mid-20s [25,48-51]. The youngest reported
age of onset was 14 years (n = 1) and the oldest was 68
years (n = 1). Initiation of NMAAS use was almost exclu-
sively an adult phenomenon; 94% commenced use at age
18 or older. The average user had used AAS, from onset to
the present, for 5.53 (sd = 5.92) years, ranging from less
than 1 year to 43 years of cycling of NMAAS. Most
(61.0%) initiated NMAAS within the first five years of
weight training.
How are AAS being used?
Training experience and practices
Users averaged 11.07 years (SD = 6.21) of weight training
and the majority (69.6%) averaged four to five workout
days per week. Most maintained a fairly standard training
regimen and few (0.90%) trained seven days per week, a
level at which some concern might be noted.
Dietary regimen
For a large majority (88.4%), the preponderance (75%) of
their daily diet "always" or "frequently" included lean
protein consumption and almost half (46.5%) reported
consuming "a lot more" than 6 to 10 servings of protein-
based foods on a daily basis. Fried food was largely
"always" or "frequently" limited (71.3%) and consumed
less than once per week (77.6%); three-quarters (76.2%)
limited saturated fat intake. Most (73.2%) consumed "a
lot less" than one sugar-containing soft drink daily, with
many (41%) restricting carbohydrates to "a lot less" or "a
little less" than seven servings per week. More than one-
quarter (26.4%) reported consuming about 3 to 5 servings
of milk daily, with an additional 44.7% consuming "a lit-
tle" or "a lot more" and 28.9% consuming "a lot" or "a lit-
tle less". The majority reported consumption of less than
3 to 5 servings of fruit (62%) or vegetables (48.1%) daily.
Cycling of NMAAS
AAS are typically cycled, with periods of use interspersed
with periods of recovery/abstinence, to allow the endo-
crine systems of the body to return to homeostasis. There
was considerable variability in cycle length (range of 1
week [n = 1] to 728 weeks [n = 1]), with a median of 11
weeks. Most had administered AAS for a total of 5 of the
preceding 12 months; 13.5% had not used AAS during the
past year and 5% had used AAS for the entire previous
year. The average year included 4 to 6 months of use; how-
ever several (16.8%) did not answer or could not provide
an estimate due to variability in their cycling history. The
modal longest on-cycle period was 12 weeks.
Cycle planning and preparation
Most ("75–100%") AAS needed for a cycle were obtained
prior to beginning a cycle by most users (80%). Ninety-six
percent planned the length, dosages and compounds
prior to beginning a cycle; 2/3 (69.3%) "always" kept to
their predetermined plan and an additional 30.6% "fre-
quently" did so. Cycles were altered to increase (18.7%,)
or decrease (13%) dosages or to avoid side effects (11%).
Finances (3.5%) or an inability to obtain desired AAS
(6.5%) were not factors for most. An additional 1.6%
indicated that alterations to their cycle stemmed from
work and personal life-related issues or injury. Of those
(5%) not planning their cycles, most determined their use
based on body response and goals.
Motivation for AAS Use Figure 10
Motivation for AAS Use.
Motivation for AAS Use N Mean Rating* SD
 Increase muscle mass 1821 4.71 0.6
 Increase strength 1797 4.28 0.91
 To look good 1798 4.19 1.06
 Increase confidence 1775 3.578 1.37
 Decrease fat 1790 3.576 1.26
 Improve mood 1765 3.23 1.46
 Attract sexual partners 1772 3.16 1.51
 Prevent injury 1754 2.969 1.45
 Recreational weightlifting 1718 2.968 1.41
 Increase endurance 1759 2.79 1.47
 Amateur bodybuilding 1754 2.27 1.47
 Amateur/recreational sports 1729 2.11 1.33
 Power lifting 1733 2.01 1.36
 Professional bodybuilding 1721 1.6 1.13
 Professional sports 1728 1.45 1.06
*Rating scale = 1 (not a reason for use), 2 (of little importance), 3 (somewhat 
important), 4 (important), 5 (very important)
Percent of Respondents who are Current Athletes Figure 11
Percent of Respondents who are Current Athletes.
89%
11%
No
YesJournal of the International Society of Sports Nutrition 2007, 4:12 http://www.jissn.com/content/4/1/12
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Injection practices
Injection has been noted as the most common method of
self-administration of NMAAS [24,52] and our data
showed this as well; a vast majority injected AAS (95%).
Sharing of needles or multi-use vials was denied by an
overwhelming majority (99%); a finding also consistent
with other reviews [53-55]. Reusing of needles was rare
(0.7%) and most (73%) used a clean needle to draw the
solution into the syringe and a separate needle to inject.
Infections resulting from injection were rare (7%).
Injectable AAS were preferred over oral compounds by
most (77%), with health reasons and the belief of better
results in comparison to oral AAS considered important.
To a lesser extent, the ability to maintain a stable blood
level was somewhat important, while ease of use, how the
AAS made the individual feel, and the inability to obtain
injectable AAS were of lesser importance.
Medical supervision of NMAAS
Most (66%) expressed a willingness to seek medical
supervision and the preponderance (61%) obtained
blood work at least once per year to assess the effects of
NMAAS use on their physical health. However, NMAAS
users often mistrust physicians and consider them uni-
formed regarding NMAAS [56]. Accordingly, more than
half (58%) lacked sufficient trust in their physician to
report their NMAAS use; 92% felt the medical commu-
nity's knowledge about NMAAS use was lacking. In addi-
tion, almost all (99%) felt that the public has an inflamed
view of NMAAS side effects.
Discussion
Who is using AAS?
NMAAS is largely an adult phenomenon; the median user
was twenty-nine years old, agreeing with earlier reports
[25,32]. Users were typically unmarried Caucasians in
their 20s and 30s who initiated NMAAS use after reaching
the age of majority. They were not active in organized
sports. They were highly educated, gainfully employed,
white collar workers earning an above average income;
such high levels of functioning in terms of education,
income, and employment are consistent findings [9,25]
and are inconsistent with the popular view of substance
abusers. In total, our findings belie the images of AAS
users as mostly risk-taking teenagers, cheating athletes,
and a group akin to traditional drug abusers.
One possible limitation is our use of the Internet and the
potential bias toward a higher-functioning group. How-
ever, the similarities of this sample with others employing
different methodologies [25,32,53] minimizes this con-
cern. Because the Internet is now a primary source for
both purchasing AAS [31] and NMAAS information [32],
a wide range of users are likely familiar and comfortable
with its use. Hence, our sample likely represents the non-
elite athlete, adult NMAAS using population. Further, the
use of the Internet controlled for potential geographical
variation in NMAAS prevalence and related behaviors
[53,57,58]. Finally, the Internet facilitated access to a large
sample – the largest, to our knowledge, ever collected.
NMAAS use was rarely associated with athletics; most
users did not compete in sports of any kind. In fact, rela-
tively few had participated in high school sport and few
reported using AAS at that time in their life. Contrary to
portrayals of coaches and athletes as the primary consum-
ers of AAS, only eight respondents were athletes or
coaches by occupation; the results in this large sample
agreed with those using smaller samples [25,32,52,59];
recreational weightlifters comprised almost 90% of our
sample, also similar to reports from other reviewers [24].
NMAAS may, indeed, be prevalent among elite athletes,
but competitive athletes are few among NMAAS users.
Cheating in sport is a rare motivation for NMAAS and the
small number of professional athletes using AAS generally
competed in power sport events (e.g., power lifting, wres-
tling, football, full contact fighting). Interestingly,
NMAAS was also reported in unexpected professional
sports, such as rodeo, dance and tennis.
Bias must also be considered as a possible cause for low
prevalence of athletes in our sample. The extent to which
athletes use the Internet, both in general and as a source
for AAS or for NMAAS information or read bodybuilding
magazines is unknown. Competitive athletes may be less
likely to volunteer to participate and provide such sensi-
tive information. Conversely, as noted previously, the
observed consistency between our findings and those
from smaller datasets [59] suggests we have tapped the
same population and we would expect that with the Inter-
net serving as the primary source of AAS trade, athletes
should be represented.
The largest yet least visible group of NMAAS users is recre-
ational weightlifters with more varied reasons for use than
competitive athletics [51,60]; "...a great deal of anabolic
steroid use occurs in private gymnasia (non-local author-
ity) among non-competitive recreational athletes [51]"
and "...noncompetitive recreational users make up a large
portion of the AAS-using population [25]." Our findings
agree with this ubiquitous observation[10,25,32,51,58,
60].
What is being used?
Injectable AAS were most popular and preferred, due
largely to decreased liver toxicity as compared to oral
agents. Almost 10% exclusively injected AAS, having
never used oral agents. Contrary to traditional notions
that injection reflects escalation in drug use, intra-muscu-Journal of the International Society of Sports Nutrition 2007, 4:12 http://www.jissn.com/content/4/1/12
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lar (IM) injection of AAS avoids several of the more seri-
ous potential side effects of NMAAS and may be a less
risky approach. Oral AAS are associated with liver damage
[59,61] and IM injection of AAS "...could therefore be
considered a rational attempt to reduce harm rather than
an element of escalating use [9]" and may be "...more
advisable... [62]." The prevalence and preference of inject-
ing AAS suggests that injection should be considered the
normative route of administration; a positive finding, in a
public health sense, due to its potential reduction of
harm.
Despite having reduced hepatotoxicity, intramuscular
injection is not without potential complications; a small
minority reported injection-site infection. Still, unlike
other groups of illicit drug users [63-65], sharing of nee-
dles and multi-use vials, and reuse of needles were almost
non-existent. The use of separate needles to draw and
inject oil-based products was the standard approach.
NMAAS users in general seemed to practice safe injection
techniques [51,66] and NMAAS use apparently "...present
[s] little risk of HIV transmission" [66] or other blood
borne pathogens [53]. Accordingly, viral hepatitis and
HIV infection were not reported by anyone in our sample.
Why are AAS being used?
Sports and competitive bodybuilding did not motivate
NMAAS use in this group. Amateur sports, bodybuilding
and power lifting were rarely cited as motivators. Consist-
ent with this, few acknowledged a fear of losing athletic
abilities if they ceased AAS use.
The primary motivations for NMAAS were increased mus-
cle mass, strength and physical attractiveness. Loss of
muscle and strength were important concerns should
access to NMAAS cease. Negative reinforcement (avoid-
ance motivation) was not as important as positive rein-
forcement (anticipated gains) in NMAAS; positive effects
were endorsed more frequently and highly than were con-
cerns about avoiding negative effects upon cessation.
Overall, cessation of AAS use was not a concern for many
users. Although low self-esteem certainly may motivate
some AAS users, it was not a primary motivator. In fact,
loss of respect was the least endorsed fear. The most parsi-
monious explanation seems to be that NMAAS respond-
ents, like most people, have an idea of how they wish to
appear and, as a goal-directed group, adopted a structured
NMAAS regimen, along with diet, exercise and other sup-
portive components to attain a desired physique or out-
come.
NMAAS appeared to be more associated with an image of
the ideal (attractive) body structure and ability as large,
muscular and powerful, a view that is consistent with
Western ideals, and not with an aversion towards being
small. Positive changes in strength and muscularity were
more highly endorsed than were avoidance of loss of
these characteristics. This is a subtle but important distinc-
tion; it suggests a desire to enhance one's physique, even
when it leads to use of NMAAS, as motivation, as opposed
to body dissatisfaction as psychopathology which leads to
AAS use [67]. It is clear, however, that we did not measure
satisfaction or dissatisfaction with current physique on
our sample. Nonetheless, it has been noted that "...people
actively use body image to achieve certain ends, justify
particular actions and manage particular identities [68]"
and AAS-using and non-using gym goers have comparable
concerns about body image [69]. Hence, in goal-oriented
NMAAS users, the desire for an improved physique may
not reflect dissatisfaction with one's current physique but
part of a strategy aimed at self-improvement and achiev-
ing their goals. Interestingly, even though increases in
body esteem associated with NMAAS allegedly remitted
after cessation of use [70], becoming less attractive upon
cessation did not concern this group.
The top three motivators among this sample replicated
those in two Australian surveys [i.e., [25,71]]. Wright and
colleagues (2001) [62] also found increased muscle mass
as the primary motivating factor. The use of AAS for fit-
ness-related and cosmetic purposes is widely reported
[7,8,24,47,71-74] and NMAAS use has been discussed as
a form of appearance enhancement similar to plastic sur-
gery [75]. Our data adds to a literature that suggests that
users may consider NMAAS use as a means to enhance
normal functioning, which is a growing trend in our soci-
ety [76].
Motivations for use were generally stable across age
groups, consistent with the observation by Brower, Elipu-
los, Blow, Catlin, & Beresford [27], (1990) that "...older
and younger subjects did not appear to differ." It might
have been expected that motivations for use would
change with development, given the changing nature of
roles across the lifespan. The minor differences that did
appear primarily were associated with typical age-related
biological changes (e.g., motivations for increasing endur-
ance, decreasing fat); however, they may also reflect psy-
chosocial development (e.g., attracting sexual partners,
increases in confidence). In any case, although statistically
significant, the magnitude of these age-related changes
was less than might be expected.
It has been suggested [77] that many AAS users experience
a "high" from use, although others [78] found such
reports to be rare. Our results agree with the latter notion;
the great preponderance of our respondents (99%)
denied that immediate psychogenic effects (e.g., intoxica-
tion, arousal or euphoria) motivated their use, dose, dura-
tion or frequency of use, suggesting that they did notJournal of the International Society of Sports Nutrition 2007, 4:12 http://www.jissn.com/content/4/1/12
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experience AAS as euphorigenic [6,72] and did not inject
for a "high."
When are AAS being used?
Initiation of NMAAS use was an adult phenomenon;
onset occurred in the great majority (94%) after reaching
eighteen years of age and only 6% of current users initi-
ated NMAAS prior to that age. Reports of age of onset in
the literature vary; our results agree with some reports [21]
but not others [79]. It appears, however, that the typical
adult male American using AAS initiated NMAAS in his
mid-twenties [see also [24,25]], within 5 years of begin-
ning weight training. This does not minimize concerns
about adolescent NMAAS; significant numbers of adoles-
cents are experimenting with AAS (although surveys sug-
gest that many more experiment with and use other
drugs). But adolescent onset of use was rare among ongo-
ing adult users, suggesting a discontinuity between adult
NMAAS and adolescent experimentation. Adolescent
experimentation may be qualitatively different than adult
use, given the developmental issues involved in adoles-
cent drug use/experimentation, and may not invariably
lead to longer-term use. Of course, the best data to explore
this issue would come from true longitudinal studies as
opposed to retrospective reports of onset. Nonetheless,
given the potential negative effects of adolescent use,
research efforts should focus on exploring adolescents'
patterns of and motivations for NMAAS to more fully
inform identification of those at risk and efforts to prevent
use.
Ultimately, in the absence of longitudinal studies [80], it
is impossible to make definitive statements about the rela-
tionship between patterns of initiation and long-term use.
It is noteworthy that the prevalence of adult onset we
observed differs from the pattern of initiation seen in
other drugs [e.g., alcohol; [81]] where early onset predicts
later use. However, research has shown clear distinction
between AAS users and those using other generally illicit
drugs [82].
How are AAS being used?
The overall fitness and lifestyle context in which NMAAS
is embedded is likely inconsistent with widespread use; as
Korkia [58] (1994) noted, few "...are prepared to take reg-
ular and vigorous exercise like weight-training, which
must accompany AS use, and therefore it is unlikely that
AS use would reach epidemic proportions." This is the
context of NMAAS; the majority of users maintained a
strenuous regular training regimen, lifting weights 4–5
days per week, as well as a strict dietary regimen high in
protein and low in fats and sugars.
AAS were used about six months per year, broken up into
3 month periods, reflecting common cycling practices
employed to allow the body to return to homeostasis.
Periods of use were largely planned in great detail and the
necessary drugs were most often in hand ahead of time.
Ancillary drugs – drugs used to prevent or treat AAS
related side effects or make AAS more effective – were rel-
atively commonplace. NMAAS users utilize SERMs (i.e.,
clomid [clomiphene citrate], nolvadex [tamoxifen citrate]
which block estrogen receptors) or aromatase inhibitors
(i.e., arimidex [anastrozole] which block the conversion
of AAS into estrogen) because in an attempt to maintain
homeostasis, the body converts excess androgens into
estrogen, resulting in unwanted side effects. The use of
peptides (i.e., HGH, IGF-1, insulin) has received little
attention in the realm of NMAAS users; however the avail-
ability of recumbent forms of peptides has lead to greater
use of these hormones by non-athletes [83]. HGH,
although taken with AAS, is often combined with insulin
or thyroid hormones (t3/t4). Insulin, familiar to many
only as a medication used in the treatment of diabetes, is
a very anabolic compound that shuttles needed nutrients
to muscles, produces growth factors when combined with
HGH in the liver and combats insulin resistance produced
by HGH. Thyroid hormones burn fat and NMAAS users
may combine them with HGH to increase their levels
which is reduced by HGH.
This data raises two interesting points. First, NMAAS
involves more forethought and organization than other
illicit drug use; it is less impulsive and more considered.
The planned cycling, healthy diet, ancillary drugs, blood
work, and mitigation of harm via route of administration
suggest a strategic approach meant to maximize benefits
and minimize harm. Second, pre-planning required users
to obtain most of their planned cycle prior to beginning.
Hence, unlike other illicit drugs procured by end-users in
single or short-term use quantities, AAS users are likely to
have substantial amounts of AAS on hand for long-term
personal use. To achieve supraphysiological levels of ster-
oid hormones, many respondents used up to 12 meth-
androstenolone tablets (5 mg each) per day, with a few
using over 20 tablets. This reasonably necessitates an ini-
tial possession of 1,000 tablets or more for personal use
(consistent with anecdotal observations of AAS purchas-
ing patterns; [84]). Such quantities, in the case of single-
use illicit drugs, would suggest intent to distribute; in
NMAAS they are more likely an on-hand quantity for per-
sonal use. The legal implications of this are that some AAS
users may be improperly accused of trafficking based
solely upon the quantity recovered.
AAS users are well known for being educated on the drugs
they use and most seek information about AAS at least
monthly [25]. Most recognized the value of medical
supervision and regular blood work, but did not trust
their physician enough to inform them of their NMAAS.Journal of the International Society of Sports Nutrition 2007, 4:12 http://www.jissn.com/content/4/1/12
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Consistent with other studies [56,69], they almost univer-
sally lacked confidence in physicians knowledge of AAS; a
sentiment with which physicians seem to agree [60]. As a
result, NMAAS users seek information from various non-
medical sources [62].
Conclusion
The picture of NMAAS use reported herein confirms and
extends much of what previous research has shown about
this subject. It differs from the common impression held
by the media and public. High-functioning NMAAS users
of approximately 30 years of age who do not compete ath-
letically receive little attention in the larger discussion of
NMAAS use and also bear little resemblance to the illicit
drug abuser to whom they are often compared. These
findings suggest that one size does not fit all.
These results suggest that most attempts to address
NMAAS use have been off-target. NMAAS use emerged
from the community of elite athletes, but it spread to non-
athletes, where it is now more prevalent. The targeting of
athletes through drug testing and other interventions does
little to address use among non-competitive users. Addi-
tionally, condemnations of NMAAS use based on misuse
by adolescents, even when it is purportedly associated
with tragic deaths, do little to address use among the vast
majority of users; they are not adolescents.
Attempts to devalue the accomplishments of sports fig-
ures accused of NMAAS are fraught with unintended con-
sequences; communicating social and moral
admonishment of "cheating" as a means to curtail use
also highlights what may be seen as otherwise unattaina-
ble achievements, thus perhaps perpetuating use. We
found NMAAS users to be a driven and ambitious group
dedicated to gym attendance, diet, occupational and edu-
cational attainment. They view AAS as a form of enhance-
ment that, when approached in an informed fashion is
seen to have an acceptable cost/benefit ratio. They do not
simply self-administer AAS and expect positive effects or
achieve goals; most use AAS in conjunction with consid-
erable effort, including strict diet and workout regimens.
The vast bulk of AAS users are not athletes and hence, are
not likely to view themselves as cheaters, but rather as
individuals using directed drug technology as one part of
a strategy for physical self-improvement. In fact, this per-
ception parallels current social trends; the use of medica-
tions and medical technology for enhancement is a
growing phenomenon in our society [76].
A seeming contradiction runs through our data. In spite of
possible limitations of the Internet for data collection, the
segment of the population engaged in NMAAS that we
accessed was an active, young, well-educated, and health-
focused group. This health-centered lifestyle may seem
clearly inconsistent with the potential complications of
NMAAS. However, at least in the case of this sample, the
use of AAS appeared well-considered; most attempt to use
AAS  responsibly, adopting what are perceived as safer
routes of administration and hygienic injection practices,
consuming a healthy diet, employing methods to reduce
side effects, obtaining regular blood work, and periodi-
cally cycling on and off AAS.
Obviously none of this justifies NMAAS. But prevalence
rates of NMAAS are at best stable, if not increasing, in spite
of prevention programs, augmented law enforcement
attention, increased legal penalties, state-mandated high
school steroid testing programs, and various stricter sanc-
tions by professional and amateur sports organizations.
This disparity between levels of use and efforts to curtail it
may largely reflect the virtually invisible nature of the larg-
est segment of the AAS-using population: adult non-ath-
letes. In contrast to current policies, several have called for
harm reduction [60,62]. We, along with our colleagues
[62], believe that if a harm reduction policy has merit, it
must begin by regaining NMAAS users' trust. That process
starts with looking beyond the conventional portrait of
NMAAS to further explore how and why these drugs are
used in the vast majority of users.
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